<DOC>
	<DOCNO>NCT02357901</DOCNO>
	<brief_summary>This randomize , double-blind , placebo control , multisite study male female participant seek treatment opioid use disorder .</brief_summary>
	<brief_title>Treatment Seeking Participants With Opioid Use Disorders Assessing Tolerability Depot Injections Buprenorphine</brief_title>
	<detailed_description>Participants induct sublingual film strip . This 24-week non-residential study participant randomize meeting criterion . On Day 1 Day 29 ( ± 2 day ) participant receive subcutaneous injection high dose placebo . Thereafter , participant receive 4 injection ( every 28 day ± 2 day ) high low dos placebo .</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Opioid-Related Disorders</mesh_term>
	<mesh_term>Buprenorphine</mesh_term>
	<criteria>Currently meet Diagnostic Statistical Manual Mental Disorders , 5th Edition ( DSM5 ) criteria moderate severe opioid use disorder By medical history meet DSM5 criterion moderate severe opioid use disorder 3 month immediately prior signing informed consent form Is seek medicationassisted treatment opioid use disorder Is appropriate candidate opioid partialagonist medicationassisted treatment opinion Investigator medically responsible physician Body mass index ( BMI ) ≥ 18.0 ≤ 35.0 kg/m^2 Current diagnosis opioid use disorder require chronic opioid treatment Current substance use disorder define DSM5 criterion regard substance opioids , cocaine , cannabis , tobacco , alcohol . Positive urine drug screen ( UDS ) result screen cocaine cannabis AND meet DSM5 criterion either moderate severe cocaine cannabis use disorder , respectively Meets DSM5 criterion moderate severe alcohol use disorder Received medicationassisted treatment opioid use disorder ( e.g. , methadone , buprenorphine ) 90 day prior provide write informed consent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>